Here, we present a Cas9-based exon23 deletion protocol to restore dystrophin expression in iPSC from Dmdmdx mouse-derived skin fibroblasts and directly differentiate iPSCs into myogenic progenitor cells (MPC) using the Tet-on MyoD activation system.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
Here, we present a Cas9-based exon23 deletion protocol to restore dystrophin expression in iPSC from Dmdmdx mouse-derived skin fibroblasts and directly differentiate iPSCs into myogenic progenitor cells (MPC) using the Tet-on MyoD activation system.
Duchenne muscular dystrophy (DMD) is a severe progressive muscle disease caused by mutations in the dystrophin gene, which ultimately leads to the exhaustion of muscle progenitor cells. Clustered regularly interspaced short palindromic repeats/CRISPR-associated 9 (CRISPR/Cas9) gene editing has the potential to restore the expression of the dystrophin gene. Autologous induced pluripotent stem cells (iPSCs)-derived muscle progenitor cells (MPC) can replenish the stem/progenitor cell pool, repair damage, and prevent further complications in DMD without causing an immune response. In this study, we introduce a combination of CRISPR/Cas9 and non-integrated iPSC technologies to obtain muscle progenitors with recovered dystrophin protein expression. Briefly, we use a non-integrating Sendai vector to establish an iPSC line from dermal fibroblasts of Dmdmdx mice. We then use the CRISPR/Cas9 deletion strategy to restore dystrophin expression through a non-homologous end joining of the reframed dystrophin gene. After PCR validation of exon23 depletion in three colonies from 94 picked iPSC colonies, we differentiate iPSC into MPC by doxycycline (Dox)-induced expression of MyoD, a key transcription factor playing a significant role in regulating muscle differentiation. Our results show the feasibility of using CRISPR/Cas9 deletion strategy to restore dystrophin expression in iPSC-derived MPC, which has significant potential for developing future therapies for the treatment of DMD.
Duchenne muscular dystrophy (DMD) is one of the most common muscular dystrophies and is characterized by the absence of dystrophin, affecting 1 of approximately 5,000 newborn boys worldwide1. Loss of dystrophin gene function results in structural muscle defects leading to progressive myofibers degeneration1,2. Recombinant adeno-associated virus (rAAV)-mediated gene therapy system has been tested to restore the dystrophin expression and improve muscle function, such as gene replacement using micro-dystrophins (µ-Dys). However, the rAAV approach requires repeated injections to sustai....
Access restricted. Please log in or start a trial to view this content.
All animal handling and surgical procedures were performed by a protocol approved by the Augusta University Institutional Animal Care and Use Committee (IACUC). Mice were fed standard diet and water ad libitum.
1. Isolation of primary mouse fibroblasts from adult Dmdmdx mice
Access restricted. Please log in or start a trial to view this content.
Establishment of Dmdmdx skin fibroblasts derived iPSC. We demonstrated the efficiency of generating mouse iPSCs from Dmdmdx mice derived skin fibroblast using the integration-free reprogramming vectors. Figure 1A demonstrated that the appearance of embryonic stem cell (ESC)-like colonies at three weeks after infection. We evaluate the efficiency of iPSC induction by live alkaline phosphatase (AP) stain; Figure 1B s.......
Access restricted. Please log in or start a trial to view this content.
Duchenne Muscular Dystrophy (DMD) is a destructive and ultimately fatal hereditary disease characterized by a lack of dystrophin, leading to progressive muscle atrophy1,2. Our results demonstrate the restored dystrophin gene expression in Dmdmdx iPSC-derived myogenic progenitor cells by the approach of CRISPR/Cas9-mediated exon23 deletion. This approach has three advantages.
First, we generated iPSCs from Dmdmdx m.......
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
Tang and Weintraub were partially supported by NIH-AR070029, NIH-HL086555, NIH-HL134354.
....Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| Surgical Instruments | |||
| 31-gauge needle | Various | ||
| Sharp Incision | Various | ||
| Sterile Scalpels | Various | ||
| Tweezers | Various | ||
| Fibroblast medium (for 100 mL of complete medium) | Company | Catalog Number | Volume |
| 2-Mercaptoethanol (55 mM) | Gibco | 21-985-023 | 0.1 mL |
| Antibiotic Antimycotic Slution 100x | CORNING | MT30004CI | 1 mL |
| Dulbecco's Modified Eagle's Medium - high glucose | SIGMA | D6429 | 87 mL |
| Fetal Bovine Serum Characterized | HyClone | SH30396.03 | 10 mL |
| L-Glutamine solution | SIGMA | G7513 | 1 mL |
| MEM Non-Essential Amino Acids Solution (100x) | Gibco | 11140076 | 1 mL |
| TVP solution (for 500 mL of complete solution) | Company | Catalog Number | Volume |
| Chicken Serum | Gibco | 16110-082 | 5 mL |
| EDTA | Sigma-Aldrich | E6758 | 186 mg |
| Phosphat-buffered saline | to 500 mL | ||
| Trypsin (2.5%) | Thermo | 15090046 | 5 mL |
| mES growth medium(for 500 mL of complete solution) | Company | Catalog Number | Volume |
| 2-Mercaptoethanol (55 mM) | Gibco | 21-985-023 | 0.5 mL |
| Antibiotic Antimycotic Slution 100x | CORNING | MT30004CI | 5 mL |
| Dulbecco's Modified Eagle's Medium - high glucose | SIGMA | D6429 | 408.5 mL |
| Fetal Bovine Serum Characterized | HyClone | SH30396.03 | 75 mL |
| L-Glutamine solution | SIGMA | G7513 | 5 mL |
| Mouse recombinant Leukemia Inhibitory Factor (LIF), 0.5 x 106 U/mL | EMD Millipore Corp | CS210511 | 500 μL |
| MEK/GS3 Inhibitor Supplement | EMD Millipore Corp | CS210510-500UL | 500 μL |
| MEM Non-Essential Amino Acids Solution (100x) | Gibco | 11140076 | 5 mL |
| The ES cell media should not be stored for more than 4 weeks and with inhibitors not more than 2 weeks. | |||
| mES frozen medium(for 50 mL of complete solution) | Company | Catalog Number | Volume |
| Dimethyl sulfoxide (DMSO) | SIGMA | D2650 | 5 mL |
| Dulbecco's Modified Eagle's Medium - high glucose | SIGMA | D6429 | 24.9 mL |
| Fetal Bovine Serum Characterized | HyClone | SH30396.03 | 25 mL |
| Mouse recombinant Leukemia Inhibitory Factor (LIF), 0.5 x 106 U/mL | EMD Millipore Corp | CS210511 | 50 μL |
| Name of Material/ Equipment | Company | Catalog Number | RRID |
| 0.05% Trypsin/0.53 mM EDTA | CORNING | 25-052-CI | |
| 4% Paraformaldehyde | Thermo scientific | J19943-k2 | |
| Accutase solution | SIGMA | A6964 | Cell detachment solution |
| AgeI-HF | NEB | R3552L | |
| Alexa488-conjugated goat-anti-mouse antibody | Invitrogen | A32723 | AB_2633275 |
| Alexa488-conjugated goat-anti-rabbit antibody | Invitrogen | A32731 | AB_2633280 |
| Alexa555-conjugated goat-anti-rabbit antibody | Invitrogen | A32732 | AB_2633281 |
| anti-AFP | Thermo scientific | RB-365-A1 | AB_59574 |
| anti-α-Smooth Muscle Actin (D4K9N) XP | CST | 19245S | AB_2734735 |
| anti-Dystrophin | Thermo | PA5-32388 | AB_2549858 |
| anti-LIN28A (D1A1A) XP | CST | 8641S | AB_10997528 |
| anti-MYH2 | DSHB | mAb2F7 | AB_1157865 |
| anti-Nanog-XP | CST | 8822S | AB_11217637 |
| anti-Oct-4A (D6C8T) | CST | 83932S | AB_2721046 |
| anti-Sox2 | abcam | ab97959 | AB_2341193 |
| anti-SSEA1(MC480) | CST | 4744s | AB_1264258 |
| anti-TH (H-196) | SANTA CRUZ | sc-14007 | AB_671397 |
| Alkaline Phosphatase Live Stain (500x) | Thermo | A14353 | |
| Blasticidin S | Sigma-Aldrich | 203350 | |
| BsmBI/Esp3I | NEB | R0580L/R0734L | |
| Carbenicillin | Millipore | 205805-250MG | |
| Collagenase IV | Worthington Biochemical Corporation | LS004189 | |
| Competent Cells | TakaRa | 636763 | |
| CutSmart | NEB | B7204S | |
| CytoTune-iPS 2.0 Sendai Reprogramming Kit | Thermo | A16517 | |
| DirectPCR Lysis Reagent (cell) | VIAGEN BIOTECH | 302-C | |
| Dispase (1 U/mL) | STEMCELL Technologies | 7923 | |
| Doxycycline Hydrochloride | Fisher BioReagents | BP26535 | |
| EcoRI-HF | NEB | R3101L | |
| Fibronectin bovine plasma | SIGMA | F1141 | |
| QIAEX II Gel Extraction Kit (500) | QIAGEN | 20051 | |
| Gelatin from porcine skin, type A | SIGMA | G1890 | |
| HardSet Antifade Mounting Medium with DAPI | Vector | H-1500 | |
| Hygromycin B (50 mg/mL) | Invitrogen | 10687010 | |
| Ketamine HCL Injection | HENRY SCHEIN ANIMAL HEALTH | 45822 | |
| KpnI-HF | NEB | R3142L | |
| lenti-CRISPRv2-blast | Addgene | 83480 | |
| lenti-Guide-Hygro-iRFP670 | Addgene | 99377 | |
| Lipofectamin 3000 Transfection Kit | Invitrogen | L3000015 | |
| LV-TRE-VP64-mouse MyoD-T2A-dsRedExpress2 | Addgene | 60625 | |
| LV-TRE-VP16 mouse MyoD-T2A-dsRedExpress2 | Addgene | 60626 | |
| Mouse on Mouse (M.O.M.) Basic Kit | Vector | BMK-2202 | |
| NotI-HF | NEB | R3189L | |
| Opti-MEM I Reduced Serum Media | ThermoFisher | 31985070 | |
| Polyethylene glycol 4,000 | Alfa Aesar | AAA161510B | |
| Polybrene | SIGMA | TR1003 | |
| Corning BioCoat Poly-D-Lysine/Laminin Culture Slide | CORNING | CB354688 | |
| PowerUp SYBR Green Master Mix | ThermoFisher | A25742 | |
| PrimeSTAR Max Premix | TakaRa | R045 | |
| Proteinase K | VIAGEN BIOTECH | 507-PKP | |
| Puromycin Dihydrochloride | MP Biomedicals | ICN19453980 | |
| qPCR Lentivirus Titration Kit | abm | LV900 | |
| Quick ligation kit | NEB | M2200S | |
| QIAprep Spin Miniprep Kit (250) | QIAGEN | 27106 | |
| QIAGEN Plasmid Plus Midi Kit (100) | QIAGEN | 12945 | |
| RevertAid RT Reverse Transcription Kit | Thermo scientific | K1691 | |
| RNAzol RT | Molecular Research Center, INC | RN 190 | |
| T4 DNA Ligase Reaction Buffer | NEB | B0202S | |
| T4 Polynucleotide Kinase | NEB | M0201S | |
| Terrific Broth Modified | Fisher BioReagents | BP9729-600 | |
| ViralBoost Reagent (500x) | ALSTEM | VB100 |
Access restricted. Please log in or start a trial to view this content.